Adjuvant Dabrafenib and Trametinib Treatment in Patients With Completely Resected High-risk Stage III Melanoma.

Inclusion Criteria:

- Patients with complete surgical resection of histologically confirmed AJCC (8th
edition) clinical stage III (stage IIIA [lymph node > 1mm],, IIIB, IIIC, IIID)
melanoma, in whom a decision for adjuvant treatment with dabrafenib and trametinib
has been made before entering the study;

- V600E mutation-positive cutaneous melanoma;

- ≥ 18 years of age;

- Written informed consent signed.

Exclusion Criteria:

- Lack of basic demographic and staging data.

- Current active participation in an interventional clinical trial for treatment of
melanoma.

- Pregnancy or breastfeeding women.

- Current primary diagnosis of a cancer other than melanoma, that requires systemic or
other treatment.